Close
Back to mobile site

Stifel Starts Protagonist Therapeutics (PTGX) at Buy

January 29, 2018 4:26 AM EST Send to a Friend
Stifel initiates coverage on Protagonist Therapeutics (NASDAQ: PTGX) with a Buy rating and a price target of $32.00.Analyst Adam Walsh ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login